Epilepsy Clinical Trial
— SeizS100BOfficial title:
Is Protein S100B a Predictor of First-to-chronic Seizure Conversion in Adults? A Prognostic Cohort Study
Verified date | December 2023 |
Source | Centre Hospitalier Universitaire de Nimes |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Seizures represent an important clinical problem, accounting for at least 40% of adult onset epilepsy. Predicting seizure recurrence in subjects experiencing a first seizure is difficult due to the lack of prognostic biomarkers. Recent evidence has indicated that blood-brain barrier (BBB) dysfunction constitutes an etiological factor to seizures. In particular, it has been shown that modification of BBB permeability is associated with seizure activity. In addition, it was demonstrated that BBB permeability can be assessed by measuring serum level of the protein S100B. Based on these data and considerations the investigators will test whether the extent of BBB damage at time of first seizure is predictive for seizure recurrence. The main objective of this study is to evaluate the association between the absolute (ng/ml) serum S100B levels (measured at time of the first seizure) and the experience, or not, of seizure recurrence within one year of follow-up.
Status | Completed |
Enrollment | 37 |
Est. completion date | July 30, 2020 |
Est. primary completion date | July 30, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 59 Years |
Eligibility | Inclusion Criteria: - The patient has been correctly informed. - The patient must have given his informed and signed consent. - The patient must be insured or beneficiary of a health insurance plan. - The patient is at least (=) 18 years old and less than (<) 60 years old. - The patient has experienced a first generalized, epileptic seizure (patients with partial onset and secondary generalization can also be included). - The seizure has occurred less than 24 hours ago. Exclusion Criteria: - The patient is participating in another study that may interfere with the results or conclusions of this study. - Within the past three months, the patient has participated in another study that may interfere with the results or conclusions of this study. - The patient is in an exclusion period determined by a previous study. - The patient is under judicial protection. - The patient refuses to sign the consent. - It is impossible to correctly inform the patient. - The patient is pregnant or breast-feeding (MRI contraindicated). - Patient has a previous abnormal brain imaging (MRI). - Patient has abnormal biological tests for toxicology (alcohol, cocaine and cannabis tests), blood ionogram (hyponatremia <130mM), liver enzymes (>5N), inflammatory syndrome (elevated C-reactive protein). |
Country | Name | City | State |
---|---|---|---|
France | APHM - Hôpital Nord | Marseille Cedex 20 | |
France | CHRU de Nîmes - Hôpital Universitaire Carémeau | Nîmes Cedex 09 |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier Universitaire de Nimes |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Serum S100B level | ng/ml | Day 0 (T0+6 hours) | |
Primary | Serum S100B level | ng/ml | Day 0 (T0+12 hours) | |
Primary | Seizure recurrence within 1 year | yes/no | 12 months | |
Secondary | Serum S100B level | ng/ml | Between days 14 and 28 | |
Secondary | Serum S100B level | ng/ml | 6 months | |
Secondary | Serum S100B level | ng/ml | 12 months | |
Secondary | Serum S100B level | ng/ml | at time of 2nd seizure (expected max of 12 months) | |
Secondary | Serum IL-1b level | pg/mL | Day 0 (T0+6 hours) | |
Secondary | Serum IL-1b level | pg/mL | Day 0 (T0+12 hours) | |
Secondary | Serum IL-1b level | pg/mL | Between days 14 and 28 | |
Secondary | Serum IL-6 level | pg/mL | Day 0 (T0+6 hours) | |
Secondary | Serum IL-6 level | pg/mL | Day 0 (T0+12 hours) | |
Secondary | Serum IL-6 level | pg/mL | Between days 14 and 28 | |
Secondary | Serum NSE level | µg/dL | Day 0 (T0+6 hours) | |
Secondary | Serum NSE level | µg/dL | Day 0 (T0+12 hours) | |
Secondary | Serum NSE level | µg/dL | Between days 14 and 28 | |
Secondary | Electro encephalogram profile | Day 0 | ||
Secondary | Electro encephalogram profile | Between days 14 and 28 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04595513 -
Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants
|
Phase 1/Phase 2 | |
Completed |
NCT02909387 -
Adapting Project UPLIFT for Blacks in Georgia
|
N/A | |
Completed |
NCT05552924 -
Self Acupressure on Fatigue and Sleep Quality in Epilepsy Patients
|
N/A | |
Terminated |
NCT01668654 -
Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS
|
Phase 3 | |
Not yet recruiting |
NCT05068323 -
Impact of Interictal Epileptiform Activity on Some Cognitive Domains in Newly Diagnosed Epileptic Patients
|
N/A | |
Completed |
NCT03994718 -
Creative Arts II Study
|
N/A | |
Recruiting |
NCT04076449 -
Quantitative Susceptibility Biomarker and Brain Structural Property for Cerebral Cavernous Malformation Related Epilepsy
|
||
Completed |
NCT00782249 -
Trial Comparing Different Stimulation Paradigms in Patients Treated With Vagus Nerve Stimulation for Refractory Epilepsy
|
N/A | |
Completed |
NCT03683381 -
App-based Intervention for Treating Insomnia Among Patients With Epilepsy
|
N/A | |
Recruiting |
NCT05101161 -
Neurofeedback Using Implanted Deep Brain Stimulation Electrodes
|
N/A | |
Active, not recruiting |
NCT06034353 -
Impact of Pharmacist-led Cognitive Behavioral Intervention on Adherence and Quality of Life of Epileptic Patients
|
N/A | |
Recruiting |
NCT05769933 -
Bridging Gaps in the Neuroimaging Puzzle: New Ways to Image Brain Anatomy and Function in Health and Disease Using Electroencephalography and 7 Tesla Magnetic Resonance Imaging
|
||
Not yet recruiting |
NCT06408428 -
Glioma Intraoperative MicroElectroCorticoGraphy
|
N/A | |
Not yet recruiting |
NCT05559060 -
Comorbidities of Epilepsy(Cognitive and Psychiatric Dysfunction)
|
||
Completed |
NCT02952456 -
Phenomenological Approach of Epilepsy in Patients With Epilepsy
|
||
Completed |
NCT02977208 -
Impact of Polymorphisms of OCT2 and OCTN1 on the Kinetic Disposition of Gabapentin in Patients Undergoing Chronic Use
|
Phase 4 | |
Completed |
NCT02646631 -
Behavioral and Educational Tools to Improve Epilepsy Care
|
N/A | |
Recruiting |
NCT02539134 -
TAK-935 Multiple Rising Dose Study in Healthy Participants
|
Phase 1 | |
Terminated |
NCT02757547 -
Transcranial Magnetic Stimulation for Epilepsy
|
N/A | |
Completed |
NCT02491073 -
Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL)
|
N/A |